NCT06594939View on ClinicalTrials.gov

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2029

Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
DRUG

Polatuzumab Vedotin

A combination of a monoclonal antibody and a chemotherapy drug.

DRUG

Mosunetuzumab

A monoclonal antibody.

DRUG

Cyclophosphamide

Chemotherapy drug, alkylating agent.

DRUG

Doxorubicin

Chemotherapy drug, anthracycline antibiotic.

DRUG

Prednisone

Steroid, anti-inflammatory

OTHER

Pegfilgrastim

Granulocyte stimulating factor, biologic response modifier.

Trial Locations (1)

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER